Our results also support the notion that both tumor-infiltrating Tregs and exhausted CD8 CTLs are major cellular targets of antagonistic TNFR2 antibody treatment, for the reason that both subsets of tumor-infiltrating lymphocytes express high levels of TNFR2. The gene discussed is CD8A; the disease is neoplasm.